SOUTH SAN FRANCISCO, Calif. — Twist Bioscience Corporation (NASDAQ: TWST) has unveiled a new humanized transgenic (HuTg) mouse model designed to accelerate and expand its in vivo antibody discovery services. The new platform aims to streamline the development of fully human monoclonal antibodies by generating robust immune responses and human antibody repertoires.
Unlike traditional models that require complex licensing agreements, Twist is offering HuTg access through a fee-for-service model, providing greater flexibility for researchers in terms of both budget and timeline.
“The humanized transgenic mouse model complements our current in vivo antibody discovery platforms and can be paired with our DiversimAb mouse and B cell screening platforms,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “This enables researchers to generate more candidate antibodies with greater flexibility across a range of disease areas.”
The HuTg model significantly shortens discovery timelines, allowing researchers to identify fully human antibody candidates in weeks rather than months. When combined with Twist’s DiversimAb model and B cell screening technologies, the new platform enhances epitope diversity and improves the likelihood of identifying promising therapeutic leads.
With this addition, Twist expands its end-to-end antibody discovery offerings, positioning itself as a one-stop partner for biopharmaceutical companies seeking fast, customizable solutions in therapeutic antibody development.
